U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06938321) titled 'A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer' on March 10.
Brief Summary: There're 2 parts in this interventional study:
1. The goal of phase Ib trial is to evaluate the safety and tolerability of AK130 in combination with AK112 therapy for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced biliary tract cancer (BTC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial.
2. The goal of phase II trial is to evaluate the safety and efficacy of AK...